USD 1.94
(-11.82%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | - USD | 0.0% |
2022 | - USD | 0.0% |
2021 | - USD | -100.0% |
2020 | 463.75 Thousand USD | 1218.53% |
2019 | 35.17 Thousand USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | - USD | 0.0% |
2024 Q2 | - USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2023 FY | - USD | 0.0% |
2023 Q4 | - USD | 0.0% |
2023 Q3 | - USD | 0.0% |
2023 Q1 | - USD | 0.0% |
2022 Q4 | - USD | -100.0% |
2022 Q3 | 215.7 Thousand USD | 0.0% |
2022 FY | - USD | 0.0% |
2022 Q2 | - USD | 0.0% |
2022 Q1 | - USD | 0.0% |
2021 Q1 | - USD | -100.0% |
2021 FY | - USD | -100.0% |
2021 Q4 | - USD | -100.0% |
2021 Q3 | 62.5 Thousand USD | 0.0% |
2020 FY | 463.75 Thousand USD | 1218.53% |
2020 Q4 | 463.75 Thousand USD | 0.0% |
2019 FY | 35.17 Thousand USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
AIM ImmunoTech Inc. | 495 Thousand USD | 100.0% |
Ampio Pharmaceuticals, Inc. | 274 Thousand USD | 100.0% |
Armata Pharmaceuticals, Inc. | 120.37 Million USD | 100.0% |
Actinium Pharmaceuticals, Inc. | 2.11 Million USD | 100.0% |
Azitra, Inc. | 885.94 Thousand USD | 100.0% |
Can-Fite BioPharma Ltd. | 39.99 Thousand USD | 100.0% |
Chromocell Therapeutics Corporation | 1.26 Million USD | 100.0% |
Calidi Biotherapeutics, Inc. | 7.23 Million USD | 100.0% |
CEL-SCI Corporation | 13.57 Million USD | 100.0% |
iBio, Inc. | 4.46 Million USD | 100.0% |
Lineage Cell Therapeutics, Inc. | 2.95 Million USD | 100.0% |
Matinas BioPharma Holdings, Inc. | 3.55 Million USD | 100.0% |
Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | 100.0% |
NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | 100.0% |
NanoViricides, Inc. | - USD | NaN% |
Oragenics, Inc. | 312.7 Thousand USD | 100.0% |
BiomX Inc. | 15.09 Million USD | 100.0% |
BiomX Inc. | 15.09 Million USD | 100.0% |
Protalix BioTherapeutics, Inc. | 26.28 Million USD | 100.0% |
Palatin Technologies, Inc. | 590.33 Thousand USD | 100.0% |
Scorpius Holdings, Inc. | 14.04 Million USD | 100.0% |